Pulmonary Fibrosis News Home | Pulmonary Fibrosis News
Dec 10, 2024 · Blocking HIF2 protein may promote lung repair in IPF: Mouse study. Inhibiting the HIF2 protein — fully, hypoxia-inducible factor 2 — was found to ease scarring in a mouse model of lung injury and could be a promising therapeutic strategy for treating idiopathic pulmonary fibrosis (IPF), according to the results of new preclinical research.
Pulmonary Fibrosis Symptoms, Diagnosis, Prognosis and Treatment
Recent Posts. Keeping new year’s resolutions that affect pulmonary fibrosis January 7, 2025; Enzyme responsible for fatty acid may be IPF therapeutic target January 3, 2025; Trial: LYT-100 better than Esbriet in slowing lung function decline in IPF December 20, 2024; Ways to handle the isolation that can come with the holidays December 17, …
12 Facts About Pulmonary Fibrosis Prognosis and Life Expectancy
Aug 16, 2019 · To address some misconceptions about the prognosis of pulmonary fibrosis and life expectancy of patients, we’ve put together some frequently asked questions (and answers) to help:<. What causes pulmonary fibrosis? Some cases of pulmonary fibrosis occur without known cause (this is called idiopathic pulmonary fibrosis).Other cases are caused by exposure to environmental hazards (such as ...
Blocking HIF2 protein may promote lung repair in IPF: Mouse study
2 days ago · Strides made in IPF research, but key questions remain. As with other forms of pulmonary fibrosis, IPF is characterized by progressively worsening inflammation and scarring, or fibrosis, in the lung epithelium — the protective cellular layer of the airways.Ultimately, alveoli, which are the tiny sacs responsible for gas exchange in the lungs, become damaged, leading to lung function decline ...
Pulmonary Fibrosis' End Stage: Wrestling with What to Expect
Nov 7, 2017 · One of my frustrations as a pulmonary fibrosis patient is finding solid information about what to expect as my PF progresses. I’ve asked several doctors what to expect during the end stage of PF, but often get the same answer: “We’re not there, no need to talk about that now.” I want to talk about the end stage
Study: ENV-101 improves IPF lung function, reverses fibrosis
Jun 7, 2024 · The trial also assessed the effects of treatment on key measures of lung fibrosis as assessed by high-resolution computed tomography (HRCT). Results showed treatment with ENV-101 significantly decreased the absolute percent of quantitative interstitial lung disease — which measures the extent of lung fibrosis — by 9.4%, compared with a 1.1% increase in the placebo.
Bexotegrast reverses signs of IPF lung scarring in Phase 2a trial
May 17, 2024 · The Phase 2a imaging study (NCT05621252) enrolled 10 IPF patients. Participants were randomly assigned, with seven receiving 160 mg of once-daily bexotegrast, and three given a matching placebo for 12 weeks.
Now you know: Updates from my journey living with IPF
Nov 5, 2024 · I wanted to take the opportunity this week to update you on topics I’ve discussed in several recent columns. My bronchoscopy. Diagnosed with idiopathic pulmonary fibrosis (IPF) in January 2017, I was fortunate to receive a bilateral lung transplant in July 2021. In December 2022, my care team discovered my left bronchus had narrowed.I underwent several balloon dilations, but these only ...
About Us – Pulmonary Fibrosis News
Pulmonary Fibrosis News is a digital platform intended to provide the pulmonary fibrosis (PF) community with the most recent news and information on PF, as well as first-hand community perspectives from our patient and caregiver columnists.. All articles on Pulmonary Fibrosis News are original content produced by in-house writers and editors. . …
Living With Pulmonary Fibrosis
Lifestyle changes may make living with PF easier. There are a number of things people with PF can do on a regular basis to maintain or improve their quality of life, including doing some gentle exercise, adopting a healthy diet, resting as necessary, quitting smoking, using relaxation techniques to reduce stress, joining a support group, and …